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A deﬁning characteristic of the aggressive B cell tumour Burkitt’s lymphoma (BL) is a reciprocal chro-
mosomal translocation that activates the Myc oncogene by juxtaposing it to one of the immunoglobulin
gene loci. The consequences of activating Myc include cell growth and proliferation that can lead to lym-
phomagenesis; however, as part of a fail-safe mechanism that has evolved in metazoans to reduce the
likelihood of neoplastic disease, activated oncogenes such as Myc may also induce cell death by apoptosis
and/or an irreversible block to proliferation called senescence. For lymphoma to develop it is necessary
that these latter processes are repressed. More than 95% of a subset of BL – known as endemic (e)BL
because they are largely restricted to regions of equatorial Africa and similar geographical regions – carry
latent Epstein–Barr virus (EBV) in the form of nuclear extra-chromosomal episomes. Although EBV is not
generally regarded as a driving force of BL cell proliferation, it plays an important role in the pathogenesis
of eBL. Latency-associated EBV gene products can inhibit a variety of pathways that lead to apoptosis and
senescence; therefore EBV probably counteracts the proliferation-restricting activities of deregulated Myc
lopmand so facilitates the deve
. Burkitt’s lymphoma
Burkitt’s lymphoma (BL) is a high grade, non-Hodgkin’s B cell
umour. Endemic BL (eBL) generally affects children and occasion-
lly young adults in tropical Africa and a few other geographically
eﬁned areas such as Papua New Guinea. These are equatorial
egions where malaria is hyperendemic and co-infection with
alaria parasites seems to be an important co-factor in the devel-
pment of eBL (reviewed in [1–3] and elsewhere in this volume).
p to 98% of eBL carry EBV and in the majority of cases only
he viral episome-maintenance protein EBNA1 and the non-coding
BER RNAs are expressed in the tumour cells (see later). Because
f the cellular phenotype and mutations found in immunoglobulin
ariable gene sequences, BL is generally believed to originate from
erminal centre or post-germinal centre B cells [4] and reviewed
n [5]. However, the discovery during normal EBV persistence of
ividing memory B cells expressing the EBNA1 (and EBERs) latency
rogramme seen in eBL has raised the possibility that EBV-positive
L may be derived from memory B cells that cannot exit from the
ell cycle ([3,6–8]; for a fuller discussion see later sections of this
rticle).
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Although the incidence of BL is highest in equatorial regions, it
occurs worldwide at a much lower prevalence. In contrast to eBL,
these sporadic cases of BL (sBL) are only occasionally associated
with EBV. For instance in the USA and Western Europe only about
15% of cases harbour the EBV genome. The exception here is when
BL occurs in individuals with HIV/AIDS. In AIDS patients the inci-
dence of BL is high and about 40–50% of these are EBV-positive
[9]. Regardless of their origin and EBV status, eBL and sBL are his-
tologically indistinguishable; furthermore the molecular hallmark
of every BL is a cytogenetic abnormality that deregulates the Myc
oncogene. Cell growth and proliferation in BL is driven by the consti-
tutively active Myc, and although the end result and major cellular
pathways that are disrupted are essentially similar in sBL and eBL,
we will see that the molecular details of pathogenesis differ some-
what because of the contribution of EBV latency gene products in
the latter.
2. Myc activation is a deﬁning characteristic of BL
A reciprocal chromosomal translocation between the Myc proto-
oncogene and one of three immunoglobulin genes (Ig/Myc) is a
hallmark of BL, irrespective of whether or not they carry EBV or their
Open access under CC BY license. geographical origin (reviewed in [1,10,11] and elsewhere in this vol-
ume). The three most common translocations involve a breakpoint
in the long arm of chromosome 8 at the 8q24 locus, adjacent to or
within the Myc gene. The most frequent translocation – found in
80% of cases – transposes the telomeric region of chromosome 8
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o the immunoglobulin heavy chain gene (IgH) on chromosome 14
t(8:14)]. The remainder involve either the kappa [t(2:8] or lambda
t(8:22)] immunoglobulin light chain genes (IgL). For reasons that
emain unknown, in the t(8:14) translocations associated with EBV-
arrying endemic BL, the breakpoint in Myc typically occurs more
han 100 kb upstream of the ﬁrst coding exon and the Ig breakpoint
ccurs in the VDJ region of the IgH gene. In contrast the breakpoints
n sporadic and many AIDS–BL generally occur between exons 1 and
of Myc and the IgH class switch (S) region.
Since in most cases of BL the DNA breakpoints are found in
earranged VJ regions or in S regions of the IgH loci, it is now gener-
lly accepted that these chromosomal translocations are mediated
y aberrant somatic hypermutation (SHM) or class switch recom-
ination (CSR) activity, occur in activated germinal centre (GC) B
ells and require the DNA-modifying enzyme known as activation-
nduced deaminase (AID). AID is highly expressed in GCs where it
atalyses deamination of cytidine residues, resulting in U:G mis-
atches that are processed to produce double strand (ds) DNA
reaks. These ds breaks are essential for CSR, but also occur in SHM.
here is now overwhelming evidence that activated AID can directly
ediate the translocation of Myc in GC B cells and because the JH
egion is preferentially affected and there are often signs of anti-
en selection in eBL, this has led to the attractive hypothesis that in
BV-positive BL translocation occurs as a consequence of aberrant
HM in late GC B cells [11–17].
An outcome of Ig/Myc translocation is that the proto-oncogene
s brought under the control of a transcriptionally active Ig locus,
eading to deregulated constitutive expression of the translocated
ene. In this context Myc becomes an active oncogene. As well
s facilitating chromosomal translocations, SHM can contribute to
ymphomagenesis further by mutating non-Ig genes; these may
nclude the translocated Myc genes that can accumulate mutations
n the region associated with breakpoints and often in the Myc
ransactivation domain (for example [18]).
. The consequences of Myc activation
As a result of translocation into an Ig locus in a mature B cell,
yc RNA is constitutively expressed and Myc protein accumu-
ates to higher levels than are seen in any normal B cells. This is
ue partly to the increased transcription and also in some cases
ecause mutations that introduce single amino acid substitutions
e.g. Thr58Ala) lead to stabilization of Myc protein because of
educed susceptibility to proteasome-mediated turn-over [19,20].
yc is a sequence-speciﬁc DNA-binding transcription factor and
everal high-throughput screens indicate that the Myc target-gene
etwork corresponds to about 15% of all known genes [21]. In B cells
yc appears to be particularly important, acting as a major tran-
criptional hub that links a hierarchy of multiple sub-hubs directly
r indirectly regulating the transcription of a vast number of genes
22,23].
Targets of Myc include groups of genes regulating cell cycle pro-
ression, cell growth (including metabolism, ribosome biogenesis,
rotein synthesis and energy production) apoptosis and senescence
[21,24–26]; Fig. 1). Stimulation of global protein synthesis by Myc
irectly augments cell size and this alone is probably sufﬁcient to
nitiate cell cycle progression [27,28]. This induction of global pro-
ein synthesis and accompanying alteration in translational control
ppears to be a rate-limiting determinant of cancer initiation by
yc. Moreover it was found in murine B cells that activated Mycnduces supernumerary centrosomes and genomic instability that
s also dependent on the deregulation of protein synthesis [28].
vidently the aberrant induction of cell growth is central to the
ole of Myc as an oncoprotein. Further insight into Myc’s oncogenic
otency is also emerging with the demonstration that it regulatesiology 19 (2009) 366–376 367
and is regulated by a network of micro-RNAs (miRNAs) involved in
the modulation of tumorigenesis [29–33].
The net effect of deregulating and over-expressing Myc is cell
growth, uncontrolled proliferation but also a reduced threshold
for the induction of apoptosis. Myc translocation in mature B cells
is therefore accompanied by rapid mitogen-independent cell divi-
sion, but a concomitant increase in the rate of cell death. Consistent
with this, the histological appearance of BL and the behaviour of
explanted cells in culture both indicate that BL cells have a high
proliferative index but are very prone to apoptosis [1].
4. Myc-induced apoptosis—a central role for p53
The seminal discovery that Myc can actually trigger rapid apop-
tosis (as well as proliferation), led to the hypothesis that apoptotic
pathways must be disabled for oncogenes to promote cell transfor-
mation and cancer [24,34,35]. This in turn led to the concepts of
‘oncogenic stress’ and ‘intrinsic tumour suppression’ and descrip-
tions of fail-safe mechanisms that prevent deregulated oncogenes
inducing neoplastic disease [36,37]. Mouse models that were estab-
lished to mimic the translocation of Myc in B cells and its role in
lymphomagenesis have been very fruitful in revealing the nature
of Myc-responsive fail-safe mechanisms. Deregulated expression
of Myc in B cells – activated by placing it under the control the IgH
enhancer (E-Myc) – induces the accumulation and activation of
the tumour suppressor p53. This is largely because Myc stimulates,
via E2F transcription factors, expression of the gene in the CDKN2A
locus known as p19ARF in mice and p14ARF in humans. The ARF pro-
teins interact with and antagonise the negative regulator of p53
called MDM2 [38–40]. Apoptosis is then induced primarily by p53
accumulating and transactivating genes that encode pro-apoptotic
proteins such as Bax, Bid, Noxa and Puma rather than genes such as
p21WAF1 that induce cell cycle arrest [41,42]. Additionally, p53 may
directly activate the apoptotic machinery by initiating the release
of cytochrome c from mitochondria [43].
In mice carrying an E-Myc transgene, most clonal B lymphomas
arise with either p53-mutations or p19ARF deletions or they over-
express MDM2. In BL it has been reported that about 30% of BL
and up to 70% of BL-derived cell lines carry p53-mutations. More-
over, those BL with wild type p53 sometimes over-express MDM2
or lose p14ARF expression by homozygous gene deletion or promoter
methylation [44]. It seems that many, but not all, Myc-driven lym-
phomas acquire genetic or epigenetic changes that compromise the
ARF/MDM2/p53 axis and so avoid Myc-induced apoptosis.
5. The special relationship between Myc and Bim
The ‘intrinsic’ or ‘mitochondrial’ apoptosis pathway is initiated
by BH3 (Bcl-2 homology domain 3)-only proteins (including Bad,
Bid, Bik, Bim, Noxa and Puma); these are a pro-apoptotic sub-
group of the Bcl-2-family. To kill cells they all require the action
of the Bax/Bak pro-apoptotic family members and the ‘intrin-
sic/mitochondrial’ pathway is regulated by the inhibitory action
of Bcl-2 (the prototype) and other anti-apoptotic members of the
Bcl-2-family, for example Bcl-XL and Bﬂ-1 [45].
The pro-apoptotic family member Bim [Bcl-2-interacting
mediator of cell death also known as Bcl-2-like protein 11
(BCL2L11)] acts as a potent, direct initiator of apoptosis because
it binds with high afﬁnity to Bcl-2 and all the other pro-survival
family members to inactivate them. Bim also binds and activates
pro-apoptotic Bax to initiate cytochrome c release from mito-
chondria [45,46]. Bim is particularly important in the immune
system, acting as a major regulator of life-and-death decisions dur-
ing lymphocyte development including the negative selection of
auto-reactive B cells and developmentally programmed death of
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sig. 1. Pro- and anti-proliferative consequences of deregulating the proto-oncogene
ize lead to cell division. Proliferation is enhanced by speciﬁc induction of cyclins D
nduced by at least two pathways: either the induction of p14ARF leading to an incre
14ARF/p53 and also the induction of the cdki p16INK4a. For references see text. Verti
ow-afﬁnity antibody-expressing germinal centre-derived B cells
45,47,48]. Bim −/− mice accumulate excess lymphoid and myeloid
ells and loss of Bim accelerates B-lymphomagenesis induced by
n E-Myc transgene. Even loss of a single allele of Bim accelerates
ymphomagenesis signiﬁcantly, indicating Bim is a haploinsufﬁ-
ient tumour suppressor and that the level of Bim protein is a
ritical rate-limiting factor in B cell survival [49]. Consistent with
his, recent studies have revealed deletions or methylation of the
im locus in a variety of human B lymphomas ([50,51] and our
npublished observations).
In E-Myc mice with normal Bim, B lymphomas arise with rel-
tively low penetrance (often over more than a year) and in most
umours the p19ARF/MDM2/p53 pro-apoptotic tumour-suppressor
athway has been inactivated (usually by mutation of p53 or
19ARF). However, in Bim −/− E-Myc mice, tumours arise much
ore rapidly and the selection pressure for functional inactiva-
ion of the p53 apoptotic pathway appears to be removed [49].
xtending this mouse model of Myc-induced lymphoma to human
ymphomagenesis, Lowe and colleagues revealed a very speciﬁc
elationship between Myc and Bim in the pathogenesis of BL [52]. As
e have seen, deregulated Myc is a hallmark of all BL and sometimes
oint mutations, probably arising as the result of aberrant AID dur-
ng SHM, are found in the translocated Myc alleles. These mutations
ave a tendency to cluster in conserved box 1 (residues 44–65).
wo common mutants of Myc that are found in BL – Pro57Ser and
hr58Ala – retain their ability to stimulate proliferation and acti-
ate p14ARF and p53, but are defective at promoting apoptosis. This is
ecause – unlike wild type Myc – they fail to induce the expression
f Bim when over-expressed [52]. Since tumours carrying codon 57
r 58 mutations of Myc often retain a functional p53 pathway, but
ild type Myc is generally accompanied by genetic lesions in the
53 pathway, it has been proposed that Myc-induced apoptosis is
ependent on a cell tipping over a delicately balanced death thresh-
ld. Survival therefore involves inactivation of any one of several
yc effectors (e.g. p14/p19ARF, p53 or Bim) to cause apoptosis-ﬁring
o drop below the critical threshold and allow cell proliferation and
he development of a tumour [37,52,53].
. Myc, senescence and the CDKN2A locus
Oncogenic stress initiated by the inappropriate activation of
ncogenes not only triggers apoptosis, but also, in certain circum-
tances, initiates a cell cycle arrest and a phenotype resembling that
f aged, senescent cells. This is known as premature senescence
nd is generally characterised by an increase in the levels of several
ffectors of arrest that include p14ARF, p53, p21WAF1 and p16INK4a
54,55]. Although the responses that focus on the CDKN2A locus
that encodes both p14ARF and p16INK4a as the result of alternative
plicing and reading frames) are generally associated with aberrant
ignalling from the oncoproteins Ras and Raf, Myc also targets thisncreased protein synthesis and energy production and the resulting increase in cell
, and the repression of the cyclin-dependent kinase inhibitor p27KIP1. Apoptosis is
p53 or the induction of Bim. Senescence may also be initiated via the induction of
rows indicate increases or decreases.
locus. As we have seen, the response to Myc is most commonly the
initiation of apoptosis via p14ARF and p53, but there is some evi-
dence that Myc can also up-regulate p16INK4a in human cells [25].
The molecular circuitry is probably very complex and may involve
the repressor of transcription and Polycomb group (PcG) protein
Bmi-1. Myc operationally cooperates with Bmi-1 in the induction
of mouse lymphomas and the simplest interpretation is that while
Myc activates the CDKN2A locus inducing apoptosis or arrest, Bmi-1
in a polycomb complex mediates repression of the locus via targeted
epigenetic histone modiﬁcations and so the balance is shifted in
favour of survival and proliferation [25,37].
It is clear why activation of Myc in lymphomas would be accom-
panied by genetic or epigenetic lesions that suppress apoptosis, but
the link between Myc and senescence in B cells is less apparent.
However, since the p16INK4a promoter commonly becomes methy-
lated at CpG dinucleotides in BL, this indicates that suppression of
the growth arrest/senescence pathway is probably important in the
pathogenesis of BL [44,56].
7. EBV latency
EBV is the -herpesvirus associated with eBL and like all -
herpesviruses is characterised by a tropism for lymphocytes and its
ability to persist for the life of the infected host. In vitro, EBV can very
efﬁciently induce the activation and continuous proliferation of
resting human B cells [57]. This process is known as B cell transfor-
mation or immortalization, and the resulting lymphoblastoid cell
lines (LCLs) carry the viral genome as extra-chromosomal episomes
and express only nine ‘latent’ EBV proteins. There are six nuclear
antigens (EBNAs 1, 2, 3A, 3B, 3C and LP) and three membrane-
associated proteins (LMP1, LMP2A and 2B). In addition two species
of non-coding RNA are expressed (the EBV-encoded RNAs [EBERs]
and the BamH1A rightward transcripts [BARTs]). Together these
viral factors activate quiescent B cells from G0 into the cell cycle,
initiate and sustain proliferation and maintain the viral episome
in its extra-chromosomal state (reviewed in [57]). Current data
on the asymptomatic life-long persistence of EBV in humans are
consistent with the viral genome residing long-term in a resting
memory B cell population rather than an LCL-like population of
proliferating B-blasts. To establish persistence, EBV infects resting
(naïve) B cells and drives these to proliferate transiently as acti-
vated B-blasts. This expansion of activated B cells is accompanied
by their differentiation to become centroblasts, then centrocytes
and ﬁnally resting memory B cells (Fig. 2A). Although the pre-
cise series of events that the EBV-positive B cells undergo to reach
the memory compartment remains uncertain, it occurs in germi-
nal centres [8] and involves the regulated shut-down of latent EBV
gene expression from an initial state called latency III (as found
in LCLs), via latency II (EBNA1, LMP1, LMP2 and the EBERs) until
in quiescent memory B cells no EBV proteins can be detected in
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Fig. 2. (A) EBV persistence. In vivo, EBV is thought to utilize normal B cell development and differentiation pathways to gain access to its site of long-term persistence, the
memory B cell. The schematic is based on the model proposed by Thorley-Lawson and colleagues and is described more fully in the text. (B) Models of BL pathogenesis. (I) A
naïve B cell infected with EBV expresses the latency III programme and is driven to proliferate. EBNA3A and EBNA3C are expressed and this can lead to the epigenetic repression
of Bim. EBNA2 is down-regulated as the cells to differentiate into germinal centre (GC) cells. They now express only EBNA1, the LMPs and EBER RNAs but transcription of Bim
is now signiﬁcantly impaired. Ig/Myc translocation occurs during somatic hypermutation (SHM) and leads to uncontrolled proliferation. The deregulated Myc is potentially
lethal, however, the prior repression of Bim transcription (and perhaps similar repression of p14ARF and p16INK4a) allows the cell to survive and proliferate. LMP1 and LMP2A
may also repress apoptosis via NF-B, Ras/PI3K/AKT and ERK/MAPK pathways and EBNA1 may prevent Myc-induced accumulation of p53. Myc-driven proliferation prevents
the latently infected cell from becoming a resting memory cell and since the progeny remain in the division cycle, EBNA1 is expressed. The balance between proliferation
and apoptosis will be maintained by the epigenetic repression of Bim (and perhaps other genes) together with the anti-apoptotic activities of EBNA1. (II) It is possible that
during the pathogenesis of BL EBV might infect and rescue a GC B cell that has already sustained an Ig/Myc translocation. Such a cell may have entered a GC as the result
of antigen (Ag) stimulation or some form of non-speciﬁc (NS) polyclonal activation as is common in malaria or HIV infections. Since latency III is the likely outcome of EBV
infection, multiple survival factors will allow this B-blast-like cell to tolerate deregulation of Myc, but precisely how it exits from a germinal centre and how switching to
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matency I would occur is presently uncertain. Although the sequence of events differ
he absence of EBV, activated naïve B cells responding to a speciﬁc antigen (Ag) or
o initiate SHM and CRS. Very rarely an Ig/Myc translocation occurs as the result of
educed. For survival the primary targets seem to be p14ARF/MDM2/p53 and Myc/Bi
yc (mut-Myc). See text for details and references.
pattern called latency 0. When EBV-positive memory B cells in
eripheral blood occasionally re-enter the cell cycle and divide in
esponse to homeostatic triggers, there is transient expression of
BNA1—a state described as latency I (reviewed in [3,58]; Fig. 2A).
entral to the growth/proliferation programme (latency III) is the
xpression of the key EBV transactivator protein EBNA2. This tran-
cription factor is critical for the activation of B cells since EBNA2
imics notch signalling, induces Myc expression and up-regulatesscenario (I), a latency III-expressing blast will again be the progenitor of BL. (III) In
peciﬁc (NS) polyclonal activation enter a germinal centre wherein AID is activated
ant CRS so the apoptosis threshold in this cell and its progeny will be dramatically
th a strong natural selection for mutations of p53 and/or codon 57/58 mutations of
the G1 cyclin D2. Central to latency-state-switching, differentiation
and entry into memory is down-regulation of EBNA2 [3,8].
Despite its asymptomatic persistence in the majority of individ-
uals, EBV has a strong association with a number of human cancers
of B cell, T cell and epithelial origin [5,59,9]. Since EBV alone is
clearly insufﬁcient for malignant transformation, other factors –
including the immune status of the infected individual and addi-
tional genetic and/or epigenetic changes within the infected cells –
370 M.J. Allday / Seminars in Cancer Biology 19 (2009) 366–376
Table 1
EBV latency gene productsa that can suppress apoptosis and/or senescence.
EBV gene product Targets Outcomes/comments References
EBNA1 USP7 Reduces p53 stability [62]
Anti-apoptotic
Anti-senescence?
Unknown Anti-apoptotic [61]
EBNA2 Nur77 Nuclear retention of Nu77 [65,66]
Anti-apoptotic
Bﬂ-1 Increases expression of Bﬂ-1 [69]
Anti-apoptotic
EBNA3A Bim With EBNA3C, represses Bim expression [76,77]
Anti-apoptotic
CDKN2A (p16INK4a) Represses p16INK4 expression [101]
Anti-senescence
EBNA3C Bim With EBNA3A, represses Bim expression [76,77]
Anti-apoptotic
CDKN2A (p16INK4a and p14ARF) Represses p16INK4a and p14ARF expression [98]; S. Maruo, personal communication;
our unpublished data
Anti-senescence
Anti-apoptotic?
LMP-1 Bcl-2, Bﬂ-1, A20 Via NF-B signalling, increases expression
of Bcl-2, Bﬂ-1, A20
[79–81]
Anti-apoptotic
p16INK4a Reduces expression of p16INK4a [102,103]
Anti-senescence
LMP-2A Bcl-xL Via Ras/PI3K/AKT can increase Bcl-xL
expression
[83–85]
Can cooperate with Myc in
lymphomagenesis
Anti-apoptotic
Bim Via ERK/MAPK may induce degradation of
Bim
[73,75]
Anti-apoptotic
miR-BART5 Puma mRNA Reduces Puma expression [90]
Anti-apoptotic
EBERs Unknown Anti-apoptotic [88]
BHRF1a Bax/Bak Binds to and inhibits Bax/Bak [91–93,95]
Suppresses Myc-induced apoptosis
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a It is currently unclear whether BHRF1 is a bona ﬁde latent gene product or whet
ytic cycle [95].
ust be involved. In addition to BL, EBV is linked to the aetiology of
wo other important B cell malignancies: Hodgkin’s lymphoma and
ost-transplant lymphoproliferative disease (PTLD). Each of these
umours has a distinct cellular phenotype (or range of phenotypes)
nd generally expresses a characteristic pattern of EBV latent genes.
his suggests that each tumour has a different aetiology and that
BV plays a distinct role in each. However it is likely that all these
ymphomas originate from EBV-infected B-blasts derived from rest-
ng B cells and that the pattern of EBV gene expression in the tumour
eﬂects that found in the corresponding type of B cell during normal
ersistence [58].
. EBV latency and apoptosis—continually re-setting the
hreshold?
During normal, asymptomatic persistence of EBV at least 4 pat-
erns of EBV gene expression are found in B cells—latency III, latency
I, latency I and latency 0 (Fig. 2A). These transcription regimes
re determined by the usage of speciﬁc EBV promoters and prob-
bly the differentiation state of the B cell. With the exception of
atency 0, which is seen in quiescent memory cells when no EBV
roteins are expressed, each of these patterns of expression is
ecapitulated in an EBV-associated B cell lymphoma: latency III
n PTLD/immunoblastic lymphomas, latency II in Hodgkin’s lym-
homa and latency I in eBL (reviewed in [57,58,60]). At least nine ofis only transiently expressed immediately after infection then again on entry to the
the EBV latency-associated gene products (summarized in Table 1)
have been linked to enhanced cell survival, are capable of re-setting
the apoptosis threshold and so might contribute to the aetiology of
EBV-positive BL.
8.1. EBNA1
EBNA1 is required for the replication and stable persistence of
EBV episomes and also transactivates the expression of other EBV
latency proteins [57]. Since it is the only EBV protein that is con-
sistently expressed in all EBV-associated cancers, there has been a
considerable research effort to determine whether it contributes
to oncogenesis, in particular by enhancing cell survival. Good
evidence from two independent experimental systems indicates
that EBNA1 has anti-apoptotic activities capable of contributing
to Myc-associated lymphomagenesis. Using retroviruses to deliver
dominant-negative EBNA1 into EBV-positive BL and LCL cells, Sug-
den and colleagues showed that interfering with EBNA1 activity
leads to increased apoptosis. The survival advantage imparted by
EBNA1 was not dependent on its ability to maintain EBV episomes,
nor whether the cells express a functional, wild type p53 [61]. In
contrast, the Frappier group arrived at the conclusion that EBNA1
has an anti-apoptotic activity that is mediated through p53. Using
an unbiased approach they identiﬁed the ubiquitin-speciﬁc pro-
tease USP7 (also known as HAUSP) as an EBNA1-interacting protein.
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SP7 had been shown to bind and de-ubiquitinate p53, leading
o reduced proteasome-mediated degradation and p53 stabiliza-
ion. Since EBNA1 effectively competes with p53 for USP7 binding
nd indirectly causes reduced p53 stability, it was concluded that
BNA1 would have an anti-apoptotic effect because of its capac-
ty to reduce the level of p53 [62]. Unfortunately no evidence was
rovided that this occurs in B cells latently infected with EBV and
arious other studies have shown – at least in LCLs responding to
NA damaging agents – that latent EBV does not reduce the steady
tate level of p53, block its phosphorylation and accumulation, or
mpair its function [63,64]. Although the evidence for EBNA1 hav-
ng anti-apoptotic activity is now compelling, the precise molecular
echanism remains to be determined.
.2. EBNA2
EBNA2, through a physical interaction with Nur77, protects B
ells against inducers of apoptosis that affect DNA metabolism, e.g.
-ﬂuorouracil and etoposide [65,66]. Although Nur77 is a nuclear
eceptor and transcription factor, it can translocate to mitochon-
ria, bind to Bcl-2, expose a pro-apoptotic BH3 domain on Bcl-2
nd so convert it to a death inducer [67]. It has been suggested
hat the interaction of Nur77 with EBNA2 may help retain Nur77 in
he nucleus, however an additional role for this interaction in the
odulation of Nur77-regulated transcription cannot be excluded.
he function of Nur77 as a transcription factor in the regulation of
poptosis has not been fully explored and neither has the intrigu-
ng observation that Nur77 and Bim functionally converge in the
limination of auto-reactive lymphocytes [67,68].
One of the many cellular genes that EBNA2 transactivates –
hrough its mimicry of notch signalling – is Bﬂ-1 [69]. Bﬂ-1 (also
nown as A1) is a close anti-apoptotic relative of Bcl-2 that binds
nd neutralizes Bim, and has recently been shown to play an impor-
ant role in the survival of a variety of malignant B cells [70,71]. The
BNA2-mediated induction of Bﬂ-1 complements its transcriptional
nduction by LMP1 (see below).
Despite these impressive pro-survival credentials, it is presently
nclear whether EBNA2 plays any direct anti-apoptotic role in the
athogenesis of BL unless EBV infects a B cell that has already sus-
ained an Ig/Myc translocation (see below and Fig. 2B).
.3. EBNA3A and 3C
EBNA3A, EBNA3B and EBNA3C comprise a family of nuclear pro-
eins that probably arose in the evolution of EBV by gene duplication
vents. Although they are related and share certain features, there is
othing to suggest that they have extensively redundant functions.
BNA3A and EBNA3C are essential for the efﬁcient transformation
f B cells, but EBNA3B is dispensable. Both EBNA3A and EBNA3C
ct as potent repressors of transcription when targeted to DNA and
oth possess oncogenic activity in primary rodent cells (reviewed
n [57,72]).
It has recently been shown that latent EBV can speciﬁcally and
onsistently induce a signiﬁcant reduction in the expression of Bim
73,74]. This can occur at the level of transcription and Bim protein
urnover—the latter probably via LMP2A activation of ERK/MAPK
ignalling ([73,75] and see below). Recombinant EBV with engi-
eered deletions of speciﬁc EBNA genes have demonstrated that
BNA3A and EBNA3C functionally interact to inhibit the expres-
ion of Bim in BL cells latently infected with EBV [76]. The turnover
f Bim RNA and protein seem to make little or no contribution
o this EBV-associated repression, suggesting that transcription
f Bim is the primary target in BL and LCLs. Since treatment of
BV-carrying B cells with inhibitors of histone deacetylase and
NA methyltransferase enzymes de-represses Bim, this implies that
pigenetic mechanisms of transcriptional control are involved iniology 19 (2009) 366–376 371
the down-regulation of Bim. Consistent with these data, repres-
sive marks on chromatin (e.g. reduced acetylation of histones H3
and H4, trimethylation of lysine 27 on histone H3 and CpG DNA
methylation) are found on the Bim promoter in EBV-positive BL
cells and LCLs but not EBV-negative BL or normal B cells [77].
The precise mechanism by which EBNA3A and EBNA3C mediate
repression of Bim and the potential involvement of other EBV fac-
tors requires further investigation. However, since newly infected
normal B cells express the EBV transactivator EBNA2, which consti-
tutively transactivates Myc [78] and therefore can indirectly induce
Bim expression, EBNA3A and EBNA3C may have evolved to prevent
EBNA2-induced, Bim-mediated apoptosis in infected B cells. If they
play a role in the development of BL, it is perhaps an unfortunate
side effect of this regulatory function that is required to establish
EBV latency and persistence. Since Bim is a uniquely important
tumour suppressor gene in B cells, modulation of its expression
by EBNA3A and EBNA3C is likely to be a major contributory fac-
tor in the development of any EBV-associated B lymphoma. In the
pathogenesis of BL, the data suggest that EBV, through the action
of EBNA3A and EBNA3C, is operationally equivalent to codon 57/58
mutants of Myc, since in infected cells induction of Bim by Myc
would be inhibited and Bim levels kept very low. Although EBNA3A
and EBNA3C are not generally expressed in GC B cells or eBL, their
continued expression may not be required in progeny cells for a
profound anti-apoptotic effect to be sustained in the developing
tumour as the repression of Bim they initiate and/or maintain is
epigenetic and therefore heritable. There will be a strong selec-
tion pressure to ﬁx the level of Bim transcription below a critical
threshold.
8.4. LMP1 and LMP2
LMP1 is a membrane bound signalling molecule that can drive B
cell proliferation by mimicking CD40. It also confers survival advan-
tage on cells via the transcriptional activation of NF-B-regulated
anti-apoptotic genes including Bcl-2, A20 and Bﬂ-1 [57,79–81].
However, LMP1 also up-regulates pro-apoptotic genes involved in
B cell proliferation (e.g. PAC1, clarp and Myc). The suggestion is that
while stimulating B cell proliferation LMP1-signalling coordinates
the level of pro- and anti-apoptotic proteins that is appropriate
for the proliferative state of the cell, and thus ensures survival
[82].
Like LMP1, LMP2A is a cell membrane-spanning signalling
molecule; it mimics a constitutively activated B cell receptor (BCR)
and can protect B cells from pro-apoptotic stimuli [83,84]. LMP2A
constitutively activates the Ras/PI3K/AKT signalling pathway and
this correlates with an increase in the level of anti-apoptotic Bcl-XL.
Elevation of Bcl-XL expression will neutralize pro-apoptotic Bcl-2-
family members, including Bim and Puma. LMP2A also activates
the ERK/MAPK pathway [75] and this can lead to phosphorylation of
Bim by ERK. This phosphorylation of Bim marks it for ubiquitination
and proteasome-mediated degradation. So, taken together these
data suggest that LMP2A will very effectively increase B cell survival
by two separate pathways targeting both pro-survival and death-
inducing factors. Consistent with this, it was recently reported that
LMP2A can accelerate Myc-induced lymphomagenesis in a trans-
genic mouse model that accurately mimics aspects of BL [85,86].
The available data suggest that LMP1 and LMP2A are transiently
expressed in GC B cells prior to their differentiation into memory
cells and exit from the lymph node. While they are expressed both
membrane proteins have the ability to signiﬁcantly tip the balance
of Bcl-2-family members in favour of cell survival. This may be
very important when Myc is initially deregulated but would not
be sustained when their expression is extinguished later in the
progression of eBL (see below and Fig. 2B).
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.5. BART miRNAs
A family of latent transcripts corresponding to the EBV BamH1A
ragment (BARTs) were ﬁrst described in nasopharyngeal carci-
oma (NPC)-derived cells [87]. Despite having potential coding
apacity, no protein has been identiﬁed as being translated from
hese multiply spliced transcripts in latently infected B cells
reviewed in [88]). Recently it was demonstrated that EBV is capa-
le of expressing up to 22 micro-RNAs (miRNAs) and that most of
hese are encoded in the region covered by the BARTs. This cluster
f miRNAs (the BART miRs) is robustly expressed in NPC cells, but
s either very weakly expressed or absent from EBV-carrying B cells
89]. Furthermore several of the BART miRs are unnecessary for the
ransformation of B cells, since they lie within a region of the EBV
enome that is deleted in the prototype transforming B95.8 strain
f virus [89].
One of the few BART miRs to be characterised, BART-mi5, is
f particular interest in the context of Myc activation because it
own-regulates the pro-apoptotic BH3-only protein Puma (p53-
p-regulated modulator of apoptosis) [90]. Although BART-mi5 is
ery abundant in NPC cells, preliminary data suggest it is expressed
t almost undetectable levels (or not at all) in B cell lines; however
he data on fresh BL biopsy material are not yet in. BART-mi5 is one
f the BART miRs deleted from B95.8 EBV and must therefore be
ispensable for the in vitro transformation of B cells into LCLs. Its
mportance during the establishment and maintenance of in vivo
ersistence and the pathogenesis of BL remains to be determined.
.6. EBERs
EBERs 1 and 2 are small, non-coding, non-polyadenylated RNAs
xpressed in all known forms of EBV latency. They are generally very
bundant but their mechanism of action in EBV biology and dis-
ase pathogenesis remains poorly understood (reviewed in [88]).
everal claims have been made about the anti-apoptotic effects of
he EBERs, however these are somewhat controversial. The current
onsensus of opinion is that the EBERs may furnish B cells with a
egree of protection from the pro-apoptotic activity of-interferon,
ut the molecular basis for this and signiﬁcance in BL are unknown
88].
.7. BHRF1 and BALF1
BHRF1 is an EBV Bcl-2 homologue (a vBcl-2) that binds and
nactivates Bax, directly inhibiting the mitochondrial apoptotic
achinery [91]; unsurprisingly over-expression very effectively
uppresses apoptosis, including Myc-induced apoptosis [92,93].
ALF1 is also a vBcl-2, but its role in the suppression of apoptosis
s more controversial—it is not clear whether it has anti-apoptotic
ctivity under all circumstances [94]. Because both BALF1 and
HRF1 are expressed during the lytic replication cycle of EBV and
he proteins are generally undetectable in strictly latent B cells, it
as assumed they play no role in latency. However by employ-
ng recombinant EBV-carrying speciﬁc gene deletions, Altmann and
ammerschmidt revealed a rather surprising transient burst of
HRF1 and BALF1 expression early after the infection of explanted
esting B cells that is necessary for their transformation into LCLs.
rotection from apoptosis in newly infected B-blasts therefore
ppears to be biphasic: initially BHRF1 (and probably BALF1) bind
o and directly inactivate pre-existing pro-apoptotic Bcl-2-family
embers and provide immediate protection, they are then super-
eded by the truly ‘latent’ proteins acting in a variety of ways a day
r two later (Fig. 2A and Table 1). The molecular mechanism for this
apid, transient activation of BHRF1 and BALF1 and the subsequent
witch to regular type III latency remains to be determined [95]. As
ith EBNA2, this early surge of anti-apoptotic activity could play aniology 19 (2009) 366–376
important role in eBL if EBV infects a cell with a pre-existing Ig/Myc
translocation.
9. EBV and senescence
It is unclear whether B cells can respond to oncogenic stress
by cell cycle arrest and senescence—the default pathway may be
terminal differentiation (for more detailed discussion of senescence
and differentiation pathways in B cells see [72,96]). Nevertheless, at
least three EBV latent proteins have the ability to inhibit senescence
in ﬁbroblasts exposed to an activated oncogene: EBNA3C, EBNA3A
and LMP1 all appear to rescue ﬁbroblasts from arrest induced by
oncogenic Ras and this probably involves repression of the gene
encoding p16INK4a.
9.1. EBNA3C
EBNA3C can behave like adenovirus E1A and papillomavirus
16/18 E7 proteins in oncogene cooperation assays using primary rat
embryo ﬁbroblasts, REFs. That is, it can cooperate with oncogenic
Ras (Ha-Ras) in the transformation and immortalization of REFs
[97]. Expressing Ha-Ras alone in these cells induces arrest and pre-
mature senescence associated with the induction of G1 regulators
p19/14ARF, p53 and p16INK4a (reviewed in [37]). This indicated that
EBNA3C might target the CDKN2A locus encoding both p14/19ARF
and p16INK4a. Subsequently, using an EBV conditional for EBNA3C
function made by fusing EBNA3C with a modiﬁed oestrogen recep-
tor, Maruo and colleagues showed that EBNA3C does indeed repress
expression of p16INK4a and p14ARF in LCLs. Removing the inducer of
EBNA3C activity (4-hydroxytamoxifen) from the growth medium
results in reduced proliferation and an accumulation of mRNA cor-
responding to CDKN2A and both p16INK4a and p14ARF proteins ([98];
S. Maruo, personal communication and our unpublished observa-
tions). By targeting the CDKN2A locus, in theory EBNA3C can mimic
Bmi-1, inhibit Myc-induced senescence and apoptosis, and because
in cycling cells CDKN2A is generally repressed by epigenetic mod-
iﬁcation of histones [25], there could be selection for this reduced
expression and eventually promoter DNA methylation.
9.2. EBNA3A
EBNA3A also cooperates with Ha-Ras in the transformation and
immortalization of REFs [99]. Furthermore, a 4-hydroxytamoxifen-
dependent LCL conditional for EBNA3A function showed that in the
absence of EBNA3A, cell proliferation gradually grinds to a halt.
However, although it was not reported whether this involved reg-
ulation of the CDKN2A locus [100], it has recently been reported
that repression of p16INK4a transcription in LCLs is associated with
EBNA3A expression [101]. Therefore, as with the regulation of Bim,
there is evidence that EBNA3A and EBNA3C functionally inter-
act. This is consistent with the observation that both proteins
suppress Ras-induced senescence in oncogene cooperation exper-
iments [97,99].
9.3. LMP1
LMP1 can inhibit the premature senescence induced in mouse
embryo ﬁbroblasts (MEFs) by oncogenic Ras and in the process
prevents the accumulation of p16INK4a [102]. Similar results were
obtained in IMR90 pre-senescent diploid human ﬁbroblasts. This
LMP1-mediated inhibition of p16INK4a transcription was reported
to involve the redistribution of the Ets-2 transactivator of CDKN2A,
from nucleus to cytoplasm [103]. Although all these experiments
were performed using ﬁbroblasts, it is reasonable to speculate that
LMP1 may also transiently contribute to the repression of CDKN2A
in B cells.
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0. Does latent EBV create an environment in which an
g/Myc translocation can be tolerated?
From a consideration of the preceding sections, it is obvious that
he simple answer to this question is yes—during latency in vivo EBV
an express a substantial arsenal of survival factors that would sup-
ress Myc-driven apoptosis and senescence and favour Myc-driven
roliferation. The more pertinent questions are which viral genes
re involved and in what sequence are they expressed in the patho-
enesis of BL? In the past there was considerable debate about the
ype of B cell in which the Ig/Myc translocation occurs and what
ame ﬁrst—virus or translocation? (reviewed in [11]). Nevertheless,
here is now a growing consensus that the translocation happens in
GC B cell when AID activity is high and that EBV must infect either
naïve B cell, prior to differentiation, or an activated GC B cell. In the
atter case infection could be before or after the gene translocation
vent. Three possible scenarios are considered – two involving EBV,
nd for comparison the pathogenesis of EBV-negative BL (Fig. 2B).
he ﬁrst model for EBV-positive BL ﬁts best with our current knowl-
dge of EBV biology and the molecular events in BL pathogenesis,
ut a second alternative pathway is also considered.
0.1. An EBV-infected naïve B cell as the progenitor of eBL
A naïve B cell that is infected with EBV in the tonsil expresses
he latency III programme and is driven to proliferate in part by
BNA2 activation of Myc. EBNA3A and EBNA3C are also expressed
nd this can lead to the epigenetic repression of Bim. EBNA2 expres-
ion is extinguished allowing the cells to differentiate into germinal
entre (GC) cells. They now express only EBNA1, LMP1, LMP2A and
BER RNAs (it is not known whether the BART RNAs are expressed),
owever the transcription of Bim may still be signiﬁcantly impaired.
g/Myc translocation occurs at this GC stage during SHM and leads
o uncontrolled proliferation. Because LMP1 can induce AID tran-
cription [104] this might increase the chances of aberrant or
ustained AID expression and the likelihood of a translocation
vent. The deregulated Myc is potentially lethal, since normally it
ould induce apoptosis via the p14ARF/MDM2/p53 axis and Bim.
owever, the prior repression of Bim transcription (and perhaps
imilar repression of p14ARF and p16INK4a) allows the cell to survive
nd proliferate. At this stage LMP1 and LMP2A will also repress
poptosis via NF-B, Ras/PI3K/AKT and ERK/MAPK pathways and
BNA1 may prevent Myc-induced accumulation of p53. Myc-driven
roliferation prevents the latently infected cell from becoming a
esting memory cell. Since the progeny cells remain in the division
ycle and the EBNA1 promoter used in BL cells is E2F-responsive
105,106], so EBNA1 is expressed in the growing BL. The balance
etween proliferation and apoptosis will be maintained by the epi-
enetic repression of Bim (and perhaps other genes) together with
he anti-apoptotic activities of EBNA1. Since both Myc and EBV may
nhance genomic instability (see later) then other epigenetic and/or
enetic changes that enhance tumour progression (e.g. resistance
o damaged DNA or hypoxia) will rapidly ensue and be ﬁxed by
urther natural selection.
0.2. EBV infects a GC B cell
EBV normally infects resting naïve B cells, but it is possible that
uring the pathogenesis of BL it infects and rescues a GC (or post-
C) B cell that is undergoing or has already sustained an Ig/Myc
ranslocation. Such a cell may have entered a GC as the result of anti-
en stimulation or some form of non-speciﬁc polyclonal activation
s is common in both malaria and HIV infections. All the avail-
ble data suggest that EBNA2-dependent latency III is the resulting
attern of EBV gene expression when GC and post-GC B cells are
irectly infected ex vivo [107–110]. Although we cannot be cer-iology 19 (2009) 366–376 373
tain the outcome of infecting a cycling GC cell in vivo will be the
same, it is likely that the full arsenal of EBV-encoded survival fac-
tors would initially allow B-blast-like cells to tolerate deregulation
of Myc. However this scenario is problematic since it is unclear how
these EBNA2-positive cells would exit from the germinal centre and
– most importantly – how they would switch from latency III to
latency I. Although the sequence of events differs from scenario (i),
the assumption is that a latency III-expressing blast will still be the
progenitor of BL and again any epigenetic changes (e.g. repression
of Bim) and the anti-apoptotic activities of EBNA1 will ensure the
survival and proliferation of the latency I-expressing progeny cells.
For a more detailed and informed discussion of the behaviour of
EBV-infected GC B cells, see reference [8].
10.3. EBV-negative sBL
In the absence of EBV, activated naïve B cells, responding to a
speciﬁc antigen or non-speciﬁc polyclonal activation, will migrate
to a germinal centre wherein AID is activated to initiate SHM and
CRS. In this case aberrant CRS (rather than SHM) may result in
Ig/Myc translocation. The apoptosis threshold in this cell and its
immediate progeny will be dramatically reduced and they will
be eliminated unless selection favours cells in which the balance
between apoptotic and anti-apoptotic factors is tipped in favour
of survival. Primary targets seem to be p14ARF/MDM2/p53 and
Myc/Bim, with a strong selection for pre-existing or rapidly gen-
erated mutations of p53 and/or codon 57/58 mutations of Myc that
could also result from aberrant AID activity. However, the risk of
the second oncogenic lesion occurring in the same cell will be
extremely low, no doubt accounting for the general rarity of sBL.
As with EBV-positive BL, tumour development will select further
genetic and epigenetic changes that help evade further stresses
such as hypoxia or DNA damage.
11. Myc, EBV and genomic instability
Genomic instability (GI) is a hallmark of many cancers. This is
probably because ongoing mutations associated with GI increase
the frequency of oncogenic changes that feed natural selection dur-
ing tumour progression.
In addition to its directly transforming role, evidence has been
accumulating for several years that deregulated Myc can also pro-
duce GI. By the induction of genotoxic reactive oxygen species
(ROS), Myc can evoke double-stranded DNA breaks and chro-
mosomal aberrations that in turn can initiate apoptosis via the
Atm/Chk2/p53 DNA damage response (DDR) pathway [111–113].
As a consequence the formation of Myc-driven lymphomas may
rely on suppression of not only the ARF/MDM2/p53 and Bim
tumour-suppressor pathways, but also the Atm/Chk2/p53 cascade.
Furthermore a very recent study has revealed that the aberrant con-
trol of protein synthesis in E-Myc lymphomas is also responsible
for supernumerary centrosomes, cytokinesis defects, GI and aneu-
ploidy [28]. This means that survival of Myc-driven lymphoma may
in addition require suppression of mitotic checkpoints and/or the
pathways leading to mitotic catastrophe [114].
Coincidentally, data have been accumulating that indicate latent
EBV also induces GI [115,116] and this has culminated with the
discovery by the Masucci group that EBNA1 expression in tumour-
derived B cells promotes GI via the transcriptional activation of Nox2
and induction of ROS [117]. If indeed EBNA1 generates ROS during
normal EBV latency, and as a result induces GI, then it is conceivable
that EBV has evolved suppressors of cell cycle checkpoints and/or
modiﬁers of the DDR to ensure that there are no delays or blocks to
proliferation during the establishment of persistence. Although the
data remain very sketchy, several lines of investigation suggest that
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he EBNA3 proteins (in particular EBNA3C) may occupy this role by
nhibiting G2 and/or mitotic checkpoints ([74,118–121] reviewed in
72]).
Since Myc and EBNA1 independently induce ROS and GI, one
annot exclude the possibility that in the pathogenesis of BL their
ffects are additive and that, as Masucci and colleagues suggest, this
ay be further enhanced by the expression of other viral proteins
such as EBNA3C – suppressing checkpoints [117]. The resulting
bility to survive and proliferate with severely damaged DNA could
ccount for the unexpected chromosomal complexity recently
evealed in BL by spectral karyotyping and comparative genomic
ybridization [122]. Furthermore, it may help to explain the sig-
iﬁcance of the subset of BL that retain expression of the EBNA3
roteins (also known as Wp-restricted BL [60,123,124]). Since ROS
ill induce DNA damage capable of activating the ATM/Chk2/p53
ascade this could be why classical latency I eBL often develop
utations in p53, whereas the Wp-restricted BL lines – because
hey express EBNA3s that can inhibit G2 and M checkpoints – are
ble to retain wild type p53 (see for example [76]).
2. Concluding remarks
EBV is clearly a major risk factor for most BL, and it seems likely
hat this is because EBV complements the activation of Myc by sup-
ressing the ability of deregulated Myc to induce apoptosis and
ossibly cell cycle arrest. This can result from the direct action of
BV gene products on apoptosis and/or senescence pathways at
ritical points in the development of BL. However, there is also the
ascinating prospect that by initiating epigenetic changes in the host
enome (e.g. Bim and perhaps CDKN2A or other genes) EBV may re-
rogramme B cells so that their progeny survive oncogenic stress
nd genomic instability and are more likely to become cancerous.
t is now just over 50 years since BL was described by Burkitt, about
5 years since its aetiology was linked with EBV and about 25 years
ince it was ﬁrst appreciated that chromosomal translocation of
yc to an Ig locus (rather than infection with EBV) is the deﬁning
haracteristic of the tumour. As we learn more about Myc and the
onsequences of its deregulation, so it seems we understand more
bout the role of EBV in BL. Hopefully this conceptual framework
nd these complementary lines of research will gradually lead to a
ore complete understanding of this remarkable tumour.
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